Previous 10 | Next 10 |
REDWOOD CITY, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company has executed an Assignment and Assumption of Lease for its San Carlos, California location. As a result of consolidating operations to its headq...
2023-08-16 10:08:58 ET Gainers: Novo Integrated Sciences ( NVOS ) +86% . Aeon Biopharma ( AEON ) +11% . Biophytis ( BPTS ) +10% . Syros Pharmaceuticals ( SYRS ) +9% . MediciNova ( MNOV ) +8% . Losers: Impel Pharmaceuticals...
2023-08-14 17:59:43 ET Gainers: Taysha Gene Therapies ( NASDAQ: TSHA ) +12% . Arcellx ( ACLX ) +10% . Jet.AI ( JTAI ) +10% . CompoSecure ( CMPO ) +9% . Codex ( CDXS ) +9% . Losers: Design Therapeutics ( DSGN ...
2023-08-03 16:31:33 ET Codexis press release ( NASDAQ: CDXS ): Q2 GAAP EPS of -$0.17 beats by $0.04 . Revenue of $21.32M (-44.5% Y/Y) in-line. 2023 Financial Guidance Codexis reiterated its 2023 financial guidance issued on July 20, 2023, as follows: Pr...
Company Recently Announced Enhanced Strategic Focus and Portfolio Prioritization Anticipate Demonstrating Gram-Scale Synthesis of ECO Synthesis™ Technology for RNAi Therapeutics Production by End of Year Projected Cash Runway to Mid-2026 Funds Important ECO Synthesis!...
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the launch of a new mini documentary as part of an ongoing campaign in support of World Health Day. The film showcases the Company’s recently unveiled...
2023-07-20 18:32:06 ET Codexis ( NASDAQ: CDXS ) said that as part of its strategic focus, it will streamline operations, including laying off ~25% of its staff. The enzyme engineering company said it will prioritize the advancement and marketing of its Enzyme-Catalyzed Oligonu...
Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production Codexis Expects its Pharmaceutical Manufacturing Business to Return to Growth in 2024 Company Reiterates 2023 Product Revenue Guida...
2023-07-06 17:26:36 ET Gainers: Century Therapeutics ( NASDAQ: IPSC ) +8% . Codexis ( CDXS ) +5% . Alignment Healthcare ( ALHC ) +4% . Wag! Group ( PET ) +4% . Cadiz ( CDZI ) +3% . Losers: Renalytix ( RN...
2023-06-27 17:26:51 ET Gainers: Geospace Technologies ( GEOS ) +7% . AeroVironment ( AVAV ) +6% . Codexis ( CDXS ) +5% . Recursion Pharmaceuticals ( RXRX ) +3% . CECO Environmental ( CECO ) +3% . Losers: AST SpaceMo...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...
2024-05-30 07:00:11 ET Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for CDXS on 2024-05-30 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, CDXS was trading at $3.19. CDXS currently trades -34.90% versus its...